Literature DB >> 9121505

Myoblast implantation in Duchenne muscular dystrophy: the San Francisco study.

R G Miller1, K R Sharma, G K Pavlath, E Gussoni, M Mynhier, A M Lanctot, C M Greco, L Steinman, H M Blau.   

Abstract

We evaluated myoblast implantation in 10 boys with Duchenne muscular dystrophy (DMD) and absent dystrophin (age 5-10 years) who were implanted with 100 million myoblasts in the anterior tibial muscle of one leg and placebo in the other. Cyclosporine (5 mg/kg/day) was administered for 7 months. Pre- and postimplantation (after 1 and 6 months) muscle biopsies were analyzed. Force generation (tetanic tension and maximum voluntary contraction) was measured monthly in a double-blind design. There was increased force generation in both legs of all boys, probably due to cyclosporine. Using the polymerase chain reaction, evidence of myoblast survival and dystrophin mRNA expression was obtained in 3 patients after 1 month and in 1 patient after 6 months. These studies suggest a salutary effect of cyclosporine upon muscular force generation in Duchenne muscular dystrophy; however, myoblast implantation was not effective in replacing clinically significant amounts of dystrophin in DMD muscle.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9121505     DOI: 10.1002/(sici)1097-4598(199704)20:4<469::aid-mus10>3.0.co;2-u

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  56 in total

Review 1.  Concise review: mesoangioblast and mesenchymal stem cell therapy for muscular dystrophy: progress, challenges, and future directions.

Authors:  Suzanne E Berry
Journal:  Stem Cells Transl Med       Date:  2014-11-12       Impact factor: 6.940

2.  Sparing of extraocular muscle in aging and muscular dystrophies: a myogenic precursor cell hypothesis.

Authors:  Kristen M Kallestad; Sadie L Hebert; Abby A McDonald; Mark L Daniel; Sharon R Cu; Linda K McLoon
Journal:  Exp Cell Res       Date:  2011-01-27       Impact factor: 3.905

Review 3.  Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies.

Authors:  C A Collins; J E Morgan
Journal:  Int J Exp Pathol       Date:  2003-08       Impact factor: 1.925

4.  Role of K+ channels in L-6 myoblast migration.

Authors:  Erik van Lunteren; Christopher Sankey; Michelle Moyer; Rudolf M Snajdar
Journal:  J Muscle Res Cell Motil       Date:  2002       Impact factor: 2.698

5.  The skeletal muscle satellite cell: still young and fascinating at 50.

Authors:  Zipora Yablonka-Reuveni
Journal:  J Histochem Cytochem       Date:  2011-12       Impact factor: 2.479

Review 6.  Advances in musculoskeletal tissue engineering: moving towards therapy.

Authors:  Carlo Alberto Rossi; Michela Pozzobon; Paolo De Coppi
Journal:  Organogenesis       Date:  2010 Jul-Sep       Impact factor: 2.500

7.  In vivo fluorescence imaging of muscle cell regeneration by transplanted EGFP-labeled myoblasts.

Authors:  Xiaoyin Xu; Zhong Yang; Qiang Liu; Yaming Wang
Journal:  Mol Ther       Date:  2010-02-02       Impact factor: 11.454

Review 8.  Gene therapy in large animal models of muscular dystrophy.

Authors:  Zejing Wang; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  ILAR J       Date:  2009

Review 9.  Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells.

Authors:  Francesco Saverio Tedesco; Arianna Dellavalle; Jordi Diaz-Manera; Graziella Messina; Giulio Cossu
Journal:  J Clin Invest       Date:  2010-01       Impact factor: 14.808

10.  A high-content, high-throughput siRNA screen identifies cyclin D2 as a potent regulator of muscle progenitor cell fusion and a target to enhance muscle regeneration.

Authors:  Michael V Khanjyan; Jonathan Yang; Refik Kayali; Thomas Caldwell; Carmen Bertoni
Journal:  Hum Mol Genet       Date:  2013-04-23       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.